(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | 38.9MM | +14% |
Gross Profit | 28.7MM | +6% |
Cost Of Revenue | 10.2MM | +45% |
Operating Income | -12.5MM | +12% |
Operating Expenses | 41.2MM | +8% |
Net Income | -11MM | +10% |
R&D | 4.2MM | +6% |
G&A | 8.1MM | +5% |
Marketing | 28.9MM | +9% |
Interest Expense | 890K | +1% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
SANTA CLARA, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy today announced it will report financial results for the first quarter of 2024 after market close on Monday, May 6, 2024. Management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by register
SANTA CLARA, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming Barclays 26th Annual Global Healthcare Conference in Miami. Management will be hosting a fireside chat on Tuesday, March 12, at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time. Investors interested in listening to the conference call may do so
With the business potentially at an important milestone, we thought we'd take a closer look at SI-BONE, Inc.'s...
Q4 2023 SI-BONE Inc Earnings Call
Company Sees Strong Surge in Procedure Volumes and Issues Positive 2024 Guidance
SANTA CLARA, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 Highlights (all comparisons are to the prior year period) Worldwide revenue of $38.9 million, representing an increase of ~22%U.S. revenue of $36.7 million, representing an increase of ~22%Gross Margi
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Si-Bone (SIBN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SANTA CLARA, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the fourth quarter and full year ended December 31, 2023 after market close on Monday, February 26, 2024. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference cal